U.S. Markets closed
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • Dow 30

    35,677.02
    +73.92 (+0.21%)
     
  • Nasdaq

    15,090.20
    -125.50 (-0.82%)
     
  • Russell 2000

    2,291.27
    -4.91 (-0.21%)
     
  • Gold

    1,793.10
    -3.20 (-0.18%)
     
  • EUR/USD

    1.1646
    +0.0015 (+0.1281%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • Vix

    15.43
    +0.42 (+2.80%)
     
  • GBP/USD

    1.3760
    -0.0035 (-0.2546%)
     
  • USD/JPY

    113.5300
    -0.4580 (-0.4018%)
     
  • BTC-USD

    60,707.67
    -265.01 (-0.43%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,804.85
    +96.25 (+0.34%)
     

NICE Recommends BioCryst's Hereditary Angioedema Med

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The U.K.'s National Institute for Health and Care Excellence (NICE) has recommended BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) Orladeyo (berotralstat) for hereditary angioedema (HAE).

  • The recommendation covers eligible patients 12 years and older if they have at least two attacks per month.

  • With this recommendation, patients in England, Wales, and Northern Ireland will have access to the first oral, once-daily therapy for routine prevention of recurrent HAE attacks.

  • The decision follows the European Commission marketing authorization of Orladeyo in April 2021 and approval from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2021.

  • A decision from the Scottish Medicines Consortium (SMC) for the use of Orladeyo is anticipated in the first half of 2022.

  • Read Next: BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder.

  • Price Action: BCRX stock is 0.56% lower at $14.99 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.